Skip to Content

Adamis Pharmaceuticals Corp

Rating as of

Company Profile

Business Description

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg and Symjepi (epinephrine) Injection 0.15 mg products were approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It previously announced a distribution and commercialization agreement with Sandoz to market Symjepi in the US. The company is developing additional products, including a sublingual tadalafil product candidate for the treatment of erectile dysfunction, a naloxone injection product for the treatment of opioid overdose, and metered dose inhaler and dry powder inhaler product candidates.

11682 El Camino Real, Suite 300
San Diego, CA, 92130
T +1 858 997-2400
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 171